You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Bulk Pharmaceutical API Sources for SUDAFED 12 HOUR


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for SUDAFED 12 HOUR

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Get Started Free E2750_SIGMA ⤷  Get Started Free
TCI (Tokyo Chemical Industry) ⤷  Get Started Free P1654 ⤷  Get Started Free
AKos Consulting & Solutions ⤷  Get Started Free AKOS027383893 ⤷  Get Started Free
Sigma-Aldrich ⤷  Get Started Free 1581005_USP ⤷  Get Started Free
Sigma-Aldrich ⤷  Get Started Free E1889_SIGMA ⤷  Get Started Free
Sigma-Aldrich ⤷  Get Started Free P3850000_SIAL ⤷  Get Started Free
LGC Standards ⤷  Get Started Free LGCAMP2115.00-01 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for: SUDAFED 12 HOUR

Last updated: August 4, 2025


Introduction

Sudafed 12 Hour is an over-the-counter decongestant medication primarily used to relieve nasal congestion associated with colds, allergies, and sinus issues. Its active ingredient, pseudoephedrine hydrochloride, acts as a sympathomimetic agent, constricting blood vessels in the nasal passages to reduce swelling and congestion. Given its widespread use, the procurement of high-quality bulk active pharmaceutical ingredients (APIs) for manufacturing Sudafed 12 Hour is critical. This article explores the global sources, manufacturing standards, and key considerations for sourcing pseudoephedrine hydrochloride for pharmaceutical applications.


Understanding Pseudoephedrine Hydrochloride as the API

Pseudoephedrine hydrochloride (chemical formula: C10H15NO·HCl) is a chiral compound with two enantiomers, only one of which (the decongestant-active form) exhibits therapeutic activity. Its synthesis and manufacturing are tightly regulated due to its potential for diversion into illicit methamphetamine production, especially in jurisdictions like the United States.


Global API Manufacturing Landscape

Major Pharmaceutical API Producers

The sourcing of pseudoephedrine hydrochloride typically involves a few large, established manufacturers with robust quality management systems. These producers are situated mainly in regions known for pharmaceutical manufacturing excellence, including:

  • India: Leading supplier with a significant share of the global API market. Companies such as Sun Pharma, Aurobindo Pharma, and Cipla manufacture high-quality pseudoephedrine APIs adhering to stringent quality standards like cGMP (current Good Manufacturing Practices).

  • China: Hosts numerous API manufacturers that produce pseudoephedrine hydrochloride for both domestic and export markets. Brands such as Zhejiang Medicine and Qilu Pharmaceutical are prominent.

  • Europe and the United States: While many U.S. and European companies primarily focus on formulation rather than API manufacturing, some contract manufacturing organizations (CMOs) and specialty providers offer compliant APIs meeting international standards.

Regulatory Considerations and Compliance

Given the regulatory scrutiny associated with pseudoephedrine, sourcing choices must prioritize suppliers with comprehensive compliance documentation. Manufacturers must adhere to the Drug Enforcement Administration (DEA) regulations in the U.S., Europe’s EMA standards, or equivalent local authorities.


High-Quality API Suppliers for Sudafed 12 Hour

Supplier Country Certifications & Standards Notes
Sun Pharma India WHO GMP, ISO 9001 Large-scale producer with global reach, compliant with cGMP
Aurobindo Pharma India USDMF, WHO GMP Noted for robust quality assurance practices
Cipla India OL GMP, ISO Certification Extensive experience supplying APIs for OTC medications
Zhejiang Medicine (ZMC) China cGMP compliant Leading Chinese manufacturer with international regulatory approvals
Qilu Pharmaceutical China GMP, ISO Focused on pharmaceutical intermediates and APIs

Sourcing Strategies

Direct Procurement from Manufacturers

Engaging directly with established API manufacturers ensures procurement of high-quality, certified active ingredients. This approach necessitates thorough due diligence regarding compliance certificates, batch traceability, and quality control protocols.

API Distributors and Traders

Distributors facilitate access to multiple suppliers, often providing verified quality certificates, cGMP compliance data, and logistical support. However, buyers should verify the authenticity of certifications and ensure proper documentation during procurement.

Contract Manufacturing Organizations (CMOs)

Some pharmaceutical companies opt to partner with CMOs specializing in API production and scale-up, especially when seeking to ensure cGMP adherence or to customize formulations.


Quality Assurance and Regulatory Compliance

Sourcing pseudoephedrine hydrochloride for pharmaceutical manufacturing requires adherence to strict quality standards. Ensuring the API's compliance involves:

  • Verification of Certificate of Analysis (CoA) from the supplier.

  • Confirming compliance with cGMP protocols and regulatory approvals.

  • Conducting laboratory testing of incoming API batches to validate potency, purity, residual solvents, and microbial contamination.

  • Ensuring traceability and batch documentation for regulatory audits.


Supply Chain Considerations

Given the sensitive nature of pseudoephedrine, supply chain integrity is crucial. Businesses should consider:

  • Import restrictions and diversion controls, especially in regions with stringent pseudoephedrine regulations.

  • Climate-controlled logistics to preserve API stability during transit.

  • Risk management by establishing multiple sourcing channels to mitigate shortages.


Emerging Trends and Alternative Sourcing Options

With increased regulatory oversight, some manufacturers are investing in synthesis innovations or bioengineered alternatives. Researchers are exploring non-controlled, alternative compounds that mimic pseudoephedrine's decongestant activity, although these are not yet mainstream.

Additionally, some companies are developing API manufacturing digital traceability systems to enhance transparency and authenticity verification in raw material sourcing.


Regulatory Hurdles and Legal Restrictions

Potential buyers must navigate complex legal frameworks, especially regarding the procurement of pseudoephedrine:

  • US DEA regulations restrict access, requiring license and thorough documentation.

  • EU and other jurisdictions have similar restrictions, necessitating proper licensing and reporting.

  • Export controls may limit API movement across borders, requiring compliance with local and international laws.


Conclusion

Sourcing high-quality bulk pseudoephedrine hydrochloride for Sudafed 12 Hour demands vigilance, regulatory compliance, and strategic supplier engagement. Leading manufacturers in India and China, with rigorous quality standards and certified manufacturing practices, present viable options for pharmaceutical companies. Ensuring the authenticity of certificates, maintaining robust traceability, and managing compliance are essential for uninterrupted supply and product integrity.


Key Takeaways

  • Major sourcing hubs include India and China, with numerous GMP-certified producers delivering compliant pseudoephedrine hydrochloride APIs.

  • Direct engagement with reputable manufacturers or authorized distributors mitigates risks associated with counterfeit or substandard APIs.

  • Strict adherence to regulatory and legal frameworks governing pseudoephedrine procurement is non-negotiable, especially in regulated markets like the US and EU.

  • Pharmaceutical companies should implement strong quality assurance protocols, including batch testing and documentation verification.

  • Supply chain resilience is vital; diversification of sources and logistical planning help mitigate disruptions.


FAQs

  1. What regulatory challenges are associated with sourcing pseudoephedrine hydrochloride?
    Due to pseudoephedrine’s potential for illicit use, regulators enforce strict licensing, reporting, and tracking requirements, particularly in the US, EU, and other jurisdictions.

  2. How can buyers verify the quality of bulk pseudoephedrine APIs?
    Buyers should request comprehensive Certificates of Analysis, conduct independent laboratory testing, and verify supplier certifications like cGMP compliance.

  3. Are there alternative decongestant APIs to pseudoephedrine?
    Yes, phenylephrine and oxymetazoline are alternatives, but they have different efficacy profiles and regulatory statuses.

  4. What are the consequences of sourcing substandard pseudoephedrine APIs?
    Potential consequences include product recalls, legal penalties, regulatory actions, and damage to brand reputation.

  5. How do global supply chain disruptions impact API sourcing?
    Disruptions such as geopolitical tensions, trade restrictions, or pandemic-related logistical issues can delay shipments, emphasizing the need for diversified sourcing and contingency planning.


References

[1] U.S. Drug Enforcement Agency (DEA). Regulations on Pseudoephedrine. 2022.
[2] World Health Organization (WHO). International Pharmaceutical APIs Database. 2023.
[3] European Medicines Agency (EMA). Guidelines on API Manufacturing and Quality Assurance. 2022.
[4] Industry Reports on API Market Trends. IQVIA, 2023.
[5] Patent and Regulatory Filings for Pseudoephedrine Hydrochloride Manufacturers. 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.